NEFH (Neurofilament Heavy Chain) is a neuronal intermediate filament protein encoded by the NEFH gene on chromosome 22q12.2. As the largest neurofilament subunit (molecular weight ~200 kDa), NEFH plays a critical role in maintaining axonal caliber and conducting velocity in large myelinated neurons. Neurofilament light chain (NfL) and phosphorylated NEFH are widely used as biomarkers for axonal injury in Alzheimer's disease, Parkinson's disease, ALS, and other neurodegenerative conditions.
¶ Gene Structure and Expression
The NEFH gene spans approximately 3.5 kb and contains 4 exons. It encodes a protein of 1,816 amino acids, the largest of the neurofilament subunits.
Domain structure:
- N-terminal head domain: Regulatory (phosphorylation, interactions)
- Alpha-helical rod domain: Coiled-coil formation (600 residues)
- C-terminal tail domain: KSP repeats (lysine-serine-proline), heavily phosphorylated
Expression pattern:
- Primary: Large myelinated neurons (motor neurons, sensory neurons)
- Brain regions: Spinal cord gray matter, dorsal root ganglia, cerebral cortex layer 5 pyramidal cells
- Peripheral: Peripheral nerves (sciatic, vagus)
NEFH assembles with other neurofilament subunits to form the neuronal cytoskeleton:
- Heteropolymer formation: NEFH co-assembles with NEFL (light) and NEFM (medium) subunits
- Phosphorylation-dependent assembly: Tail domain phosphorylation regulates filament spacing
- Cross-bridging: NEFH sidearms connect adjacent filaments, establishing axonal caliber
NEFH is transported along axons via:
- Slow transport: Part of the slow component a (SCa) system (~0.5 mm/day)
- Kinesin/dynactin mediated: Bidirectional movement
- Post-translational modifications: Phosphorylation state affects transport rate
The neurofilament network determines:
- Axonal diameter: Larger diameter = faster conduction velocity
- Saltatory conduction efficiency: Optimal for myelinated fibers
- Node of Ranvier organization: Neurofilament organization at paranodes
- Axonal degeneration marker: NEFL and NfL in CSF correlate with disease severity
- Tau pathology relationship: Neurofilament abnormalities occur secondary to tau pathology
- Predictive biomarker: Elevated NfL predicts cognitive decline in preclinical AD
- Longitudinal tracking: NfL levels increase with disease progression
- Axonal loss indicator: NfL in CSF reflects dopaminergic neuron degeneration
- Disease progression: Higher levels correlate with more severe motor symptoms
- DLB overlap: Elevated NfL in dementia with Lewy bodies
- Differentiation: Can help differentiate PD from atypical parkinsonism
NEFH is particularly important in ALS:
- Cytoplasmic inclusions: Phosphorylated NEFH accumulates in motor neuron spheroids
- Biomarker: NfL in CSF/blood is highly sensitive for axonal loss
- Prognostic value: Higher NfL = shorter survival
- Trial endpoint: NfL used as outcome measure in clinical trials
- Mutations: NEFH mutations cause rare forms of ALS (autosomal recessive)
| Condition |
NEFH/NfL Significance |
| Multiple Sclerosis |
Axonal injury marker, disease activity |
| Charcot-Marie-Tooth disease |
Diagnostic, severity correlation |
| Creutzfeldt-Jakob disease |
Rapidly rising NfL |
| Frontotemporal dementia |
Differentiation from AD |
| Vascular dementia |
Vascular burden indicator |
CSF (Cerebrospinal Fluid):
- NfL: Gold standard for axonal injury
- pNfH: Phosphorylated NEFH, more specific
- NFL/NEFH ratio: Disease differentiation
Blood (Plasma/Serum):
- NfL: Less invasive than lumbar puncture
- Age-adjusted cutoffs: Critical for interpretation
- Simoa technology: Ultra-sensitive detection
| Condition |
NfL Elevation |
Specificity |
| ALS |
++ (very high) |
High |
| CBD/PSP |
++ (high) |
Moderate |
| PD |
+ (mild) |
Low |
| AD |
+ (mild-moderate) |
Low-moderate |
| MS |
Variable |
Moderate |
- Neuroprotective strategies: NfL as endpoint to assess efficacy
- Axonal regeneration: Targeting neurofilament phosphorylation to enhance regrowth
- Gene therapy: NEFH overexpression to restore axonal caliber
| Protein |
Interaction Type |
Functional Significance |
| NEFL |
Co-assembly |
Intermediate filament formation |
| NEFM |
Co-assembly |
Filament structure |
| Tau (MAPT) |
Co-localization |
Axonal organization |
| Kinesin-1 |
Transport |
Axonal trafficking |
| Calmodulin |
Calcium binding |
Regulation |